HRT and Blood Clots: The Truth Behind the Fear

HRT and Blood Clots: The Truth Behind the Fear

There’s a persistent myth circulating about hormone replacement therapy that’s keeping people from treatment they need: the idea that HRT causes dangerous blood clots. It’s repeated by doctors, health websites, and concerned family members who heard it somewhere and never questioned it.

Let’s separate the fear from the facts.

Where the Blood Clot Fear Came From

The blood clot concern didn’t come from testosterone therapy. It originated with a specific type of estrogen therapy — specifically, oral synthetic estrogens like ethinyl estradiol and conjugated equine estrogens (Premarin). These older formulations, particularly when taken orally, pass through the liver and increase clotting factors.

But here’s the critical distinction that gets lost: that data came from a completely different medication, a completely different hormone, and a completely different delivery method than what’s used in modern HRT.

• Oral synthetic estrogens: Proven clotting risk, especially in older women, smokers, and those with pre-existing risk factors
• Bioidentical testosterone (injectable, transdermal, or oral undecanoate): Does NOT carry the same clotting risk profile

The media, the medical community, and the public lumped all “hormone therapy” together — and testosterone got unfairly caught in the crossfire.

What Testosterone Actually Does to Blood

If testosterone caused dangerous clotting, we’d see elevated rates of deep vein thrombosis (DVT) and pulmonary embolism in men on TRT. We don’t.

Large-scale studies of men on testosterone therapy show:

• No increase in DVT or PE rates compared to the general population
• Possible cardioprotective effects — some studies show improved cardiovascular outcomes when low testosterone is corrected (see the TRAVERSE trial data)
• Improved red blood cell production — which is actually beneficial for most men, not dangerous

Testosterone does stimulate red blood cell production (erythropoiesis), which can modestly increase hematocrit. This is routinely monitored in men on TRT. For the vast majority, it stays within safe ranges. For the small percentage where it rises too high, it’s managed by adjusting dosage, frequency, or — in rare cases — by therapeutic phlebotomy (donating blood).

Who Should Be Cautious

There are legitimate clotting risk factors that require careful evaluation before starting TRT:

• Personal or family history of unprovoked blood clots
• Known clotting disorders (Factor V Leiden, prothrombin mutation, etc.)
• Active cancer (not just history — active disease)
• Severe, uncontrolled polycythemia

But these are specific risk factors — not a blanket ban on TRT. A responsible provider evaluates your individual risk profile and makes a decision based on evidence, not fear.

The Real Risk: Untreated Hormone Deficiency

While people worry about theoretical clotting risks from TRT, they’re ignoring the documented risks of untreated low testosterone:

• Increased cardiovascular mortality
• Higher rates of metabolic syndrome and type 2 diabetes
• Increased visceral adiposity (belly fat), which IS a known clotting risk factor
• Osteoporosis and increased fracture risk
• Depression and cognitive decline

The calculus has shifted. Modern TRT, properly managed, is safer than the untreated hormone deficiency it replaces.